• Increases survival rates: PLX-R18 significantly improved survival following radiation exposure, increasing survival in treated groups vs. placebo.
• Promotes blood cell recovery: Research shows an increase in white blood cells, platelets, and red blood cells.
• Prophylactic potential: When administered before and after radiation exposure, PLX-R18 increased survival from 4% to 74% in treated groups (p<0.0001), and increase in recovery of blood lineages was observed
• Demonstrated safety: Human trials showed PLX-R18 was well tolerated with a favorable safety profile, leading to increased blood cell counts and a significant reduction in the need for transfusions.

Government Support and Regulatory Progress

• U.S. Government Collaboration: Pluri is working with the U.S. Department of Defense (DoD) and National Institutes of Health (NIH/NIAID) to advance the development of PLX-R18.
• FDA Investigational New Drug (IND) Approval: The FDA cleared PLX-R18 for study as a treatment for ARS in the event of nuclear incidents.
• Orphan Drug Designation: The FDA granted PLX-R18 Orphan Drug status for the treatment of ARS, recognizing its potential as a life-saving therapy.
• Government Funding: Pluri signed a three year $4.2M contract with NIAID for further research and development of PLX-R18.

Advancing ARS Treatment with PLX-R18

Through our collaborations with leading U.S. government agencies, Pluri is committed to developing PLX-R18 as a critical countermeasure for ARS. Our research continues to validate its safety, efficacy, and potential to save lives in the event of radiological or nuclear emergencies.

Pluri also announced it has signed an exclusive collaboration agreement with Hemafund, a Ukrainian umbilical cord blood bank, to establish a strategic initiative for stockpiling, distribution, and potential clinical advancement of PLX-R18 as a countermeasure against Hematopoietic Acute Radiation Syndrome in Ukraine.

For more information on PLX-R18 and our research, contact us today.